This further fosters an immunosuppressive TME, which constitutes one of the key factors contributing to the limited efficacy of combining radiotherapy with programmed cell death protein 1 (PD-1)/PD-L1 blockade in pancreatic ductal adenocarcinoma. The gene discussed is CD274; the disease is pancreatic ductal adenocarcinoma.